ARWR Arrowhead Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 14:46
Why ARWR matters now
Arrowhead Pharmaceuticals, Inc. (ARWR) is a US stock in Healthcare. The latest InvestLog snapshot shows $76.87 with -8.49% on the session and $10.83B in market capitalization; recent performance reads 1-month +11.81% and YTD +23.24%.
The latest financial table shown here is Q2 2026, with revenue of $73.7M, net income of $-132.7M, and EPS of $-0.93. Investors can compare that operating picture with valuation signals such as P/E 45.10 and FCF yield -0.4%.
The latest indexable market news headline is "Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $95.00; recent insider activity includes Cohen Matthew Gregory filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
45.10
PEG
0.34
P/B
18.98
P/S
18.53
EV/EBITDA
-94.52
DCF Value
$-99.57
FCF Yield
-0.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-35.7%
Net Margin
-48.4%
ROE
-55.4%
ROA
-13.3%
ROIC
-11.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $73.7M | $-132.7M | $-0.93 |
| Q1 2026 | $264.0M | $30.8M | $0.22 |
| Q4 2025 | $256.5M | $-23.8M | $-0.17 |
| FY 2025 | $829.4M | $-1.6M | $-0.01 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$84.00
Target (Median)
$95.00
Target Range
$35.00 - $110.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.27
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.